FITZSIMONS Directory

Bioscience companies located on the Fitzsimons Innovation Campus

Updated September 2017



3D Biopsy, LLC

Lab/Office: 100

Contact: Todd Anderson
612-839-2457
TAnderson@3dbiopsy.com

3DBiopsy, Inc.— founded by noted expert Drs. Stone, Crawford and Lucia—has developed a turnkey Biopsy System that uses three-dimensional (3D) imaging to map the prostate gland and correctly identifies clinically significant cancers with a 97% accuracy. It was created in response to the frustration that physicians, patients and the healthcare system experience with the current biopsy method—Transrectal Ultrasound (TRUS)—which has no more than a 50/50 chance of being accurate. The 3DBiopsy System includes a patented Biopsy Needle, patented Biopsy Actuator device, patent-pending Integrated Pathology System and 3D Mapping Software. This 4-part advance in the diagnosis and treatment of prostate cancer will result in a paradigm shift in the management of this disease—and ultimately, other cancers. A more accurate diagnosis will reduce the need for unnecessary and costly prostate removal or full gland irradiation in the majority of 825,000 newly diagnosed prostate cancer cases worldwide. With our System, as much as 67% of those patients will be spared radical treatment, and instead, be candidates for surveillance (no active treatment) or focal therapy.

Allander Biotechnologies

Lab/Office: 100

Contact: Xiao-Jing Wang
303-724-3001
xj.wang@ucdenver.edu

Allander Biotechnologies is a start-up company aiming to develop proprietary biologics to improve wound healing and treat scar, fibrotic and inflammatory disorders.

Alligant Scientific, LLC

Lab/Office: 330

Contact: Daniel Konopka
720-746-2381
danielk@alligantScientific.com

Alligant Scientific is developing new approaches to socially relevant technical problems in energy and materials science. We are a small team of motivated researchers and entrepreneurs who are pioneering innovative technologies beyond proof of concept, bringing them to life as impactful solutions for industry and people.

Alpha Omega Alpha Honor Medical Society

Lab/Office: 323

Contact: Richard Byyny
720-859-4149
r.byyny@alphaomegaalpha.org

Alpha Omega Alpha Honor Medical Society is a professional medical organization that recognizes and advocates for excellence in scholarship and the highest ideals in the profession of medicine. AΩA's values include honesty, honorable conduct, morality, virtue, unselfishness, ethical ideals, dedication to serving others, and leadership. Members have a compelling drive to do well, advance the medical profession, and exemplify the highest standards of professionalism.

Alta Biotech, LLC

Lab/Office: 217

Contact: Xiang (Sean) Liu

720-273-5839

Sean.Liu@altabiotech.com

Alta Biotech, LLC is a Contract Research Organization (CRO) providing molecular biology, biochemistry, and cell biology services to fundamental life science research, translational biomedical research, and early stage pharmaceutical development. Our mission is to deliver innovative and quality services that help customers advance scientific discovery and improve health.

Atara Biotherapeutics, Inc.

Lab/Office: 280

Contact: Scott Maxson

smaxson@atarabio.com

Atara Biotherapeutics, Inc. is a biopharmaceutical company focused on developing meaningful therapies for patients with severe and life-threatening diseases that have been underserved by scientific innovation, with an initial focus on immunotherapy and oncology.

Aurora Oncology, Inc.

Lab/Office: 125

Contact: Rick Duke

720-859-4046

Aurora Oncology Inc. will commercialize products developed by its founders as part of their research endeavors at the University of Colorado Cancer Center. The lead product, EGF-DTA fusion protein, is intended to treat recurrent bladder cancer.

Avidity, LLC

Lab/Office: 138

Contact: Larry Lansing

720-859-6111

lansing@avidity.com

https://avidity.com/

Avidity develops and sells molecular affinity tools for connecting molecules. Our patented AviTag™ technology employs a highly targeted enzymatic conjugation of a single biotin on a unique 15 amino acid peptide tag using the biotin ligase (BirA) from E. coli. Oriented on streptavidin-coated surfaces, this creates an ideal presentation for molecular binding interactions. Though Avidity is a small company, the scientific benefits of its AviTag have garnered notice. Currently, AviTag technology is licensed by seven of the world's top ten pharmaceutical companies and is used by researchers in 22 countries.

Barofold, Inc

Lab/Office: 134

Contact: Gianni Svaldi

gsvaldi@barofold.com

Barofold, Inc. acquired the exclusive world-wide rights to a patented protein dis-aggregation and re-folding technology invented by co-founders Drs. Ted Randolph and John Carpenter at the University of Colorado in May 2003. The company has received an initial contract to re-fold malarial proteins currently identifying early corporate partners, demonstrating the technology's benefits with partners' protein targets, identifying strategic partners for equipment development and manufacturing, and assessing potential pharmaceutical protein candidates for development of safer, potentially proprietary products.

Beacon Biotechnology

Lab/Office: 138

Contact: Larry Lansing

720-859-6111
lansing@avidity.com
http://beaconbiotechnology.com/

Beacon Biotechnology has taken a giant step toward realizing this dream: Beacon's BrightSPOT Reader detection platform and luciferase-based diagnostic assays combine cutting–edge hardware and novel biology in a way that is both powerful and simple. The BrightSPOT Reader will address new markets in home diagnostics, point-of-care diagnostics and bioterrorism that are limited by the shortcomings of existing technologies. The BrightSPOT Reader's ability to diagnose disease at the doctor's office will revolutionize the way medicine will be practice in the future.

Bioengineering

Lab/Office: BS2-100

Contact: Kate Hoch

303-724-6280
Kate.Hoch@UCDenver.edu
www.ucdenver.edu/Bioengineering

The Department of Bioengineering offers high quality training in bioengineering that is flexible and multidisciplinary. A design-based focus permeates every aspect of our training philosophy which can be summarized by the following question: What does the user want and how can I utilize my bioengineering training to achieve this need?

BodySync, Inc.

Lab/Office: 224

Contact: Pauline Gee

303.961-1773
pgee@bodysync.com

BodySync is a wellness company that provides customized programs based on an individual's personal genetics. The Company analyzes a discrete number of well-characterized genetic variations that have impact on nutrient metabolism and athletic performance. Each participant in a BodySync program takes a dietary and lifestyle survey to establish his/her own current dietary and wellness behavior. BodySync delivers proprietary Gene-LifeStyle™ integration of each participant's genetic and lifestyle data to provide an Action Plan. The Action Plan identifies an individual's current status and guides dietary intake and lifestyle changes in the direction of health and wellness predicated on each individual's unique genetic profile. The Company partners with Health and Wellness Solutions providers that can leverage and tailor their products to benefit each unique individual.

CariCord, Inc.

Lab/Office: 142

Contact: Calvin Cole

ccole@caricord.com
www.caricord.com

CariCord is a hybrid cord blood and tissue bank, changing the industry of stem cell banking through its partnership with the University of Colorado Medical School, processing and storing cord blood and tissue stem cells for current and future stem cell regenerative medicine and therapies.

Cerebral Therapeutics

Lab/Office: 100

Contact: Dan Abrams
303-547-3448
dan.abrams@cerebraltherapeutics.com

Cerebral Therapeutics Inc. is a privately-held company founded with the goal of addressing the well recognized limitations of existing treatments for uncontrolled neurological diseases. With a promising route of administration, Cerebral Therapeutics offers a new approach to managing neurological diseases by means of delivering ideal dosing to targeted sites within the brain. Initially, Cerebral Therapeutics is focused on improving outcomes for patients with refractory epilepsy by targeting the site of the seizure generation and propagation in the brain. Future cerebral therapeutic areas include obesity, Alzheimer's disease, Parkinson's disease, anxiety spectrum disorder and brain cancer.

Colorado Genetics Laboratory

Lab/Office: BS2-300

Contact: Kathy Taylor
303-724-5705
Kathy.Taylor@ucdenver.edu

Colorado Genetics Laboratory (CGL) is the premiere lab for cytogenetics and cytogenomics in the Rocky Mountain region. We are nationally recognized for excellence and provide state-of-the-art cytogenetic testing, as well as full interpretation of results and excellent customer service. Our Laboratory Directors and Genetic Counselors are available to discuss appropriate testing and test interpretation. Based in Aurora, CGL offers full service laboratory testing in prenatal, postnatal, cancer cytogenetics, fluorescence *in situ* hybridization (FISH), and chromosomal microarray (CMA).

Colorado Institute for Drug, Device & Diagnostic Development

Lab/Office: 126

Contact: Rick Duke
720-859-4046

Colorado Institute for Drug, Device & Diagnostic Development (CID4) provides management expertise to efficiently develop emerging life science technologies into commercial success. We do this by identifying and funding potential opportunities, and utilizing our advanced leadership team to ensure ultimate market value.
Speed to market. Long-term gains. CID4 goes for high-impact results, getting big returns from big ideas.

Colorado Molecular Correlates Laboratory

Lab/Office: BS2-300

Contact: Victoria Bingham
303-724-3087
Victoria.bingham@ucdenver.edu

The Colorado Molecular Correlates Laboratory (CMOCO) is a state-of-the-art facility, located in Bioscience 2 on the Anschutz Medical Campus/Fitzsimons Innovation Campus. The CMOCO Laboratory is dedicated to the development and implementation of predictive, prognostic and diagnostic molecular biomarker testing that will permit selection of cancer treatments with targeted therapy allowing for the best in personalized medicine.

ClinImmune

Lab/Office: BS2 - 250

Contact: Brian Freed, Ph.D., Executive Director

303-724-0535

Brian.Freed@ucdenver.edu

ClinImmune Labs comprises five laboratories:

- Histocompatibility
- Clinical Immunology
- Flow Cytometry
- University of Colorado Cord Blood Bank
- Human Stem Cell Processing facility

These laboratories provide services to kidney, heart, lung, pancreas, and hematopoietic stem cell transplant programs around the world. They are located in offices and labs in the Bioscience 2 building.

Center for Surgical Innovation

Lab/Office: 170

Contact: Sarah Massena

303-724-2756

sarah.massena@ucdenver.edu

www.ucdenver.edu/csi

The Center for Surgical Innovation (CSI) at the University of Colorado is a multidisciplinary surgical training center dedicated to promoting educational courses and development of leading edge surgical techniques and technologies. CSI was created as a local, national and international center of excellence in the evolving field of surgery. CSI is dedicated to teaching and disseminating leading edge surgical techniques to practicing surgeons, residents and medical students. Our comprehensive multi-specialty/multi-disciplinary group of faculty span all of the surgical specialties available at the University of Colorado Hospital.

DARTNet Institute

Lab/Office: 127

Contact: Wilson Pace, MD

800-434-0278 #4

Wilson.Pace@dartnet.info

www.dartnet.info

The DARTNet Institute (DI) is a not-for-profit 501c3 corporation that was created to support collaboration between Practice-based Research Networks, academic health centers, clinicians, patients and other interested parties in the use of existing electronic data and the expansion of patient or staff reported data for research, quality improvement and safety.

CU Dermatopathology Consultants

Lab/Office: 161

Contact: Nancy Jackson

303-724-9957

nancy.jackson@ucdenver.edu

www.cudermpath.com

The CU Dermatopathology Consultants perform a variety of dermatopathology services including evaluation of wet tissue, electron microscopy, consultative opinions, and direct/indirect immunofluorescence. We offer advanced immunohistochemical analysis of skin biopsies, with 143 available immunohistochemical stains and in-situ hybridization for selected disorders. We also offer limited ELISA assays to compliment our services. Our facility is certified by the College of American Pathologists (CAP) and Clinical Laboratory Improvement Amendments (CLIA). www.cudermpath.com

---

CU Innovations

Lab/Office: 270

Contact: Kim Muller
303.724.0222
Kimberly.Muller@cu.edu

The CU Innovations team with researchers and inventors at various stages during the research and technology transfer process. Our organization helps researchers with arrangements to access and share proprietary information (through confidentiality agreements) and research materials (through material transfer agreements), and to define IP terms and conditions in sponsored research agreements and consulting agreements. After an invention has been conceived, we work with inventors to: clarify the invention disclosure and identify the IP; ascertain if the IP is protectable and commercially viable; engage and assist external legal counsel to prepare the patent application and prosecute it; and contact and pursue innovative adopter companies and entrepreneurs to license the IP for further development, commercialization, and public use. Inventive activity and relationships with companies occurs in an intensely legalistic environment and university researchers are encouraged to contact CU Innovations for assistance in crafting nondisclosure agreements, reviewing consulting contracts, and protecting their intellectual property and know-how.

FindCure.Org

Lab/Office: 100G

Contact: Floyd Taub, MD
floyd.taub.md@gmail.com

FindCure.org is a 501(c)(3) non-profit organization. It investigates and facilitates the availability of immune system modulating therapies for patients with chronic conditions such as allergies, asthma, cancer, chronic fatigue syndrome, colds, fibromyalgia, flu, hay fever, hepatitis, infections, Lyme disease, lymphoma and others. FindCure.org focuses on immunotherapeutic compounds that fight disease by enhancing the immune system rather than directly attacking the disease.

Formulet, LLC

Lab/Office: 100G

Contact: Mark Spiecker
mspiecker@formulet.com

Gates Biomanufacturing Facility

Lab/Office: 380

Contact: Patrick Gaines
720-281-2100
patrick.gaines@ucdenver.edu

The Gates Biomanufacturing Facility at the University of Colorado Anschutz Campus provides the following services for cell therapies and protein-based therapeutics: Process Development, Scale up, Manufacturing to cGMP standards, and Process documentation. We also focus on delivering Academic researchers, Clinicians, and Early stage biotechnology companies. Utilizing our expertise in Quality Assurance and Control and Process Development and Manufacturing, we help translate bench scale processes to optimized clinical-ready manufacturing processes and perform product manufacturing for early-phase clinical trials. By leveraging our existing current Good Manufacturing Practice (cGMP) facilities, trained staff, qualified equipment and best practices across each of our support services, investigators can significantly accelerate their timeline while minimizing their overall investment.

Galaxy Ophthalmics, LLC

Lab/Office: 100

Contact: Fred T. Mitchell
720-262-8020

info@galaxyophthalmics.com
www.galaxyophthalmics.com

Galaxy Ophthalmics, LLC, a spinout from the University of Colorado School of Medicine, is an ophthalmic device company addressing a $1B market, Glaucoma as its first target. Galaxy developed the Wave Mini-Shunt™ to address an unmet need for the treatment of Glaucoma which allows physicians to customize the treatment of glaucoma with a degree of flexibility that is not available today. Current treatments include surgical implantation of shunts to relieve intraocular pressure (IOP), with approximately 75,000 performed in the US annually. The Wave Mini-Shunt allows ophthalmologists to gradually increase the outflow of the shunt to 'tune' the device for the patient's needs with a non-invasive procedure in the clinic using equipment they typically already have on-hand. The Wave Mini-shunt allows an unprecedented improvement in control of IOP while significantly reducing long-term surgical costs and patient risk due to replacement surgery.

Greffex

Lab/Office: 308
Contact: Uwe Staerz
303-577-0399
ustaerz@greffex.com

Greffex is the innovative global leader in the delivery of accelerated pandemic and bio-terror vaccines using the world's first universal platform, our GREVAX™ Vaccine Platform. Our proven technology, the GREVAX™ Universal Platform, a fully-deleted, helper-independent adenoviral vector system, delivers unprecedented time-to-market, cost efficiency and safety. Our vibrant pipeline of vaccines, transplantation and gene therapy products continue to create value for our people, partners and investors.

---

iC42 - UCD Department of Anesthesiology

Lab/Office: BS2-200
Contact: Uwe Christians
uwe.christians@ucdenver.edu

It is the goal of iC42 Clinical Research & Development to carry out own pre-clinical and clinical drug development programs, to assist basic science departments to bring drug candidates into clinical development and to serve as a resource for biotech and pharmaceutical industry. One of the major foci is the evaluation of pharmacokinetics, drug metabolism and the development of clinical management tools for pediatric patients.
Foremost iC42 Clinical Research & Development is a cutting-edge mass spectrometry laboratory with currently seventeen state-of-the-art LC-MS/MS systems. We are a unique facility since iC42 combines quantitative mass spectrometry (drugs, drug metabolites, other small molecules and large molecules, endogenous compounds), metabolic and protein profiling technologies under one roof. iC42 Clinical Research & Development is designed and uniquely qualified to carry out the bioanalytics for complex clinical trials involving drug quantification and molecular marker strategies.

Integrated Molecular Diagnostics Pathology, Inc.

Lab/Office: 360
Contact: Louis Tzoumbas
ltzoumbas@imdpath.com

Integrated Molecular Diagnostics Pathology, Inc. operates professional molecular laboratories specializing in advanced genomic testing. The Company solves problems presented by "standard" (non-targeted) cancer care which has historically relied on chemotherapy drugs and radiation therapy which can have adverse side effects, most specifically those of excessive toxicity and the increased risk of other forms of cancer. The Company provides pathologists and oncologists with advanced genomic testing as a means of targeting cancer care based on the detection and identification of abnormalities that may be found in cancerous tumors (otherwise referred to as the DNA Genomic Profile). Cancer treatments resultant from advanced genomic testing can be targeted, or customized, for individualized patient care providing reduced side effects from treatments and better outcomes in

patient populations where such treatment is indicated.

Immunoah Therapeutics, Inc.

Lab/Office: 222

Contact: Dr. Min Wang
303.888.2674
drminwang@gmail.com

With the amazing success of CarT and anti PD-1 drugs in last few years, cancer immunotherapy has become the most exciting and powerful tools to defeat cancer in clinic. Immunoah Therapeutics, Inc. is a biotech startup company founded by *Mile High Biomed, LLC* at Denver, Colorado in October 2016. It focuses on researching and developing proprietary antibodies in the field of cancer immunotherapy. Since 2014, Mile High Biomed, LLC has developed a group of therapeutic mABs using its novel function screening platform. Based on these early discoveries, Immunoah Therapeutics, Inc. will begin to further validate the anti-cancer functions of those moleculars. We plan to move them to pre-clinical phases in 12-24 months. Min Wang, MD is the founder and CEO; Zhe Wang, PhD. MD serves as R&D director. The company currently has a startup fund of $200,000, and is actively seeking financial support from various sources including NIH SBIR and several international investors.

ImmunoMolecular Therapeutics LLC

Lab/Office: 100

Contact: Greg Kading
303.544.2104
gkading@imtherapeutics.com

ImmunoMolecular Therapeutics is a biotechnology company engaged in the development and commercialization of innovative products for a personalized medicine approach for the treatment of autoimmune diseases, including type 1 diabetes and Celiac disease. The Company's approach employs novel and exclusive technology to modulate the activity of T cells that cause autoimmunity by using small molecules.

Invenux, LLC

Lab/Office: 222

Contact: Robert Swift
970.227.7289
riobert@invenux.com

Invenux, LLC is a privately held clinical stage biopharmaceutical company whose focus is the research and development of drugs for orphan diseases. Its first drug candidate is SCD-101 for the treatment of sickle cell disease. The primary goal of Invenux is to commercialize orphan drugs like SCD-101 through corporate partnerships that result in upfront, milestone and royalty payments or the outright sale of our rights to a pharmaceutical company.

Light Labs

Lab/Office: 180

Contact: Cary Gummelt
cary@lightlabsusa.com

Since 2002, Light Labs has successfully served the research marketplace with a wide array of laboratory goods out of their headquarters in Dallas, TX. In 2013 they set up operations in the Bioscience 1 building. Light Labs distributes PCR supplies, tissue culture supplies, pipette tips, microcentrifuge tubes, barrier tips, latex and nitrile gloves, centrifuge tubes, and much more. Stop by their store and see what they have to offer.

Living Ink Technologies

Lab/Office: 216

Contact: Scott Fulbright

scott.fulbright@livinginktechnologies.com

Living Ink transforms algae into the world's most sustainable ink. This algae-derived ink will be leveraged to enter several market verticals that includes printing needs in industries such as packaging, marketing material, business cards, signs, and invitations/stationary, as well as the pen ink production industry.

Lohocla Research Corporation

Lab/Office: 128

Contact: Dr. Boris Tabakoff

720.859.4083

boris.tabakoff@ucdenver.edu

Lohocla is a unique research and development company that analyzes the etiologic mechanisms of brain maladaptation which result in addiction to alcohol and other drugs, and produce chronic pain and major depressive disorder. Lohocla then uses "rational" drug design to generate small molecule pharmaceutics to normalize the maladapted neural systems. Lohocla has generated a molecular skeleton (platform) which it has used to create medications for reducing alcohol intake and craving in alcohol dependent individuals and has generated medications that can treat and prevent the development of several chronic pain syndromes. Lohocla's strengths in discovery and proof of concept studies are supplemented by partnerships with entities who look for early stage entry into successful medication development efforts.

Loxo Oncology

Lab/Office: 137

Contact: Stephen Michael Rothenberg

617-519-0723

rothenberg@loxooncology.com

http://www.loxooncology.com/

Loxo Oncology is committed to the discovery, development, and commercialization of targeted cancer therapies with best-in-class potential. Our diverse pipeline reflects the convergence of proven therapeutic technologies with emerging insights into the underlying susceptibilities of cancer and drug resistance. We leverage the expertise of our partners in academia and industry and our management team's deep clinical regulatory experience to deploy focused clinical development strategies in well-defined patient populations.

Our goal is to create important new cancer therapies as efficiently as possible to substantially benefit patients. Loxo Oncology derives its company name from an attendant of the Greek goddess Artemis, who represented the concept of trajectory in the sport of archery.

Machavert Pharmaceuticals

Lab/Office: 215

Contact: Gregory Miknis

Greg.Miknis@machavert.com

The goal of our company is to develop a new class of immunotherapies to unleash the power of the human body to fight against cancer or autoimmune diseases, such as psoriasis. Our approach takes advantage of a unique class of small molecules that can stimulate the human immune system to attack and destroy cancer cells or to prevent autoimmune malfunction.

Mallinda, LLC

Lab/Office: 217

Contact: Chris Kaffer
720-879-3628
chris@mallinda.com

Mallinda has advanced the state of polymer science in important ways. This includes development of the first hard plastic that can be repeatedly molded and even reshaped at mild temperatures by the end user. As a material supplier, Mallinda will create and dominate a new market of “low temperature” moldable and remoldable hard plastics and advanced composites for innovative product companies.

MBC Pharma, Inc.

Lab/Office: 214

Contact: Shawn Zinnen, Ph.D.
720.859.4040
szinnen@mbcpharma.com

MBC Pharma, Inc. is a biopharmaceutical company focused on discovering and developing drugs for bone diseases such as cancer and osteoporosis. MBC Pharma’s comprehensive and patented technology enables the highly efficient and specific delivery of drugs to bone. The approach has yielded promising lead structures in preclinical development for the treatment of multiple myeloma, metastatic bone disease caused by breast, prostate and lung cancer as well as osteoporosis and osteopenia. More Information is available at: www.mbcpharma.com

---

MenoGeniX

Lab/Office: 125

Contact: Debra Duke
DDuke@menogenix.com
www.menogenix.com

MenoGeniX is a clinical-stage biotechnology company developing MNGX-100, a therapeutic biologic, as a nonhormonal, non-SSRI/SNRI, alternative treatment for hot flashes and other vasomotor symptoms in women with natural or surgically-induced menopause as well as breast and prostate cancer patients undergoing hormone suppression or ablation. Data from a randomized, double-blind, placebo-controlled, phase Ib clinical trial in women with surgical and natural menopause, that was completed in 2014, are being used to design phase II/III clinical trials leading to registration. With a potential market of more than 70 million women worldwide seeking relief from menopause-related vasomotor symptoms without the risk associated with hormone therapy, MNGX-100 has the potential to address hot-flashes and other vasomotor symptoms, an age old unmet medical need. MenoGeniX’ goal is to find an industry partner, licensor or additional institutional investors.

MI Innovations

Lab/Office: 214

Contact: Michael Krysiak
720-308-2485
mkrysiak@mi-innovations.com

MI Innovations (MII) provides affordable Chemical/Biochemical R & D services, custom equipment and equipment modification, prototyping, short run/one off manufacturing and technical/scale-up/production consultation for startup companies to large corporations. In addition to services MI Innovations works on novel coating for micro-array diagnostics, pollution control products, electrochemical sensors and sodium and magnesium ion battery technologies. At MI Innovations we employ a vast network of internal and external expertise through robust and strategic partnerships and collaborations coupled with a full machine shop and chemical pilot scale lab to ensure efficient and cost effective solutions for any project and budget.

Mindful Labs

Lab/Office: 100

Contact: Tate Knutstad
530.848-0141
tate@getmindful.co

75% of doctor visits are stress induced. 60 million adults in the US had a mental health issue last year. Mindfulness and meditation have been proven to be just as effective in stress reduction and reducing occurrence of depression relapse as medication. Mindful Labs uses a mobile app coupled with coursework and scientific testing of hair samples to provide the most consistent and meaningful reading of cortisol in the human body. By quantifying cortisol, a biomarker for stress, Mindful Labs does for your mind what Fitbit did for your physical activity.

Nanoly Bioscience

Lab/Office: 217

Contact: Balaji Sridhar
balaji@nanoly.info
(720) 273-2875

We are developing a thermal stabilization platform technology for temperature sensitive vaccines and medicines with a patent pending photo-release formulation. We are using a safe, low cost, and scalable polymer that is well understood with a body of knowledge extending over 50 years. Nanoly Bioscience's encapsulation and photo-release approach introduces minimal changes to administrative protocol for the vaccine or medicine. Our goal is to enable immunization access anywhere while simultaneously eliminating the refrigeration cost for lifesaving medicine.

NextHerbal Labs, LLC

Lab/Office: 214

Contact: Alireza Ghaffari
a.ghafari51@gmail.com
(765) 421-2784

At NextHerbal Labs, we are dedicated to enhancing human health and well-being by formulation and launching the superior nutraceutical products (specifically, include phytochemicals).
Our immediate goal is to develop novel formulas for highly profitable and niche phytochemical/nutritional candidates in different dosage forms, i.e., tablets, capsules, chewing gums, and creams within one year. Our second goal is to apply for provisional patents for some of the sophisticated formulations – notably chewing gum. The third goal is to getting a contract manufacturer in order to figure out what to do for formulas that NextHerbal Labs intends to launch.

Omix Technologies

Lab/Office: 100

Contact: Kirk Hansen
303-815-3756
kirk.hansen@gmail.com

Omix Technologies, Inc is an S Corporation that functions solely as the owner of the two subsidiary LLCs Endura and Matriqs Biology. These two subsidiary LLCs were established to serve unique markets with different core competencies. The managing board includes Dr. Kirk Hansen, Dr. Angelo D'Alessandro, Mr. Travis Nemkov, and Mr. Ryan Hill all from the Department of Biochemistry and Molecular Genetics, School of Medicine, University of Colorado Denver.

Pathways Bioscience, Inc.

Lab/Office: 130

Contact: Brooks Hybertson
720-301-4579
hybertson@gmail.com

Pathways Bioscience, Inc. is an early stage bioscience company focused on discovering and developing new agents for modifying gene expression and regulating stress response pathways that contribute to cell defense mechanisms.

PhosphoSolutions, LLC

Lab/Office: 212

Contact: Kristin Nixon
720.859.4050
kn@phosphosolutions.com

PhosphoSolutions, LLC was created to manufacture and distribute proprietary research tools, known as phospho-specific antibodies, which are at the cutting edge of proteomics. These antibodies are a key enabling technology used by biotech companies for both discovery and validation of new drugs.
Founded by three of the world's leading scientists in protein phosphorylation, the company's unmatched expertise makes PhosphoSolutions the most qualified developer of custom-made phospho-specific antibodies.
These antibodies greatly accelerate drug discovery and research in cancer and in neurological diseases such as Alzheimer's. www.PhosphoSolutions.com

---

Precision Biopsy, LLC

Lab/Office: BS2-350

Contact: John Nichols
720-859-3553
John.nichols@precisionbiopsy.com
www.precisionbiopsy.com

Precision Biopsy is developing the first prostate biopsy system that will use light to classify tissue during biopsy procedures.

Shakabuku LLC

Lab/Office: 326

Contact: Holly Wyatt
303-724-9004
Holly.Wyatt@ucdenver.edu

Shakabuku means to remove suffering and bring happiness to all people by awakening them to their inherent greatness. Shakabuku LLC was formed because of the growing opportunity to offer transformational State of Slim weight management services at a global level to millions of people seeking to lose weight, transform their lives and awaken to their full potential. Shakabuku LLC develops and manages the global expansion and distribution of State of Slim programs, products, and related services.

Sharklet Technologies

Lab/Office: 150

Contact: Ethan Mann
720-859-4070
emann@sharklet.com
http://sharklet.com/

SHARKLET TECHNOLOGIES, LLC is a surface technology company that controls the growth of microorganisms through its revolutionary engineered topography, Sharklet™. Inspired by a shark skin pattern, Sharklet™ is the first, non-toxic, eco-friendly product ever created to truly inhibit or enhance the growth of microorganisms. There are

two primary uses for Sharklet – marine and medical industries. In the medical device industry, the Sharklet™ pattern has already shown signs of radically increasing the amount of time it takes for bacterial biofilms to develop. Sharklet is now being tested with human protein conditions present to determine if bacterial biofilm formation can be inhibited for up to 21 days.

Taiga Biotechnologies, Inc.

Lab/Office: 123

Contact: Yosef Refaeli and Brian C. Turner, Ph.D.

720.859.3557

refaeli@taigabiotech.com; turner@taigabiotech.com

Taiga Biotechnologies was founded to develop novel approaches to treat hematological diseases, including cancers, immunodeficiencies and autoimmune conditions. Our three-pronged approach combines novel breakthroughs in cellular, biologic and small molecule approaches to treat and manage these diseases.
In August 2008, Taiga received its first small business innovation research grant from the Department of Health and Human Services, National Institute of Allergy and Infectious Disease. The grant will be used to further develop the proprietary technology to rapidly generate human therapeutic antibodies against influenza.
In September 2008, Taiga received its second small business innovation research grant from the Department of Health and Human Services, National Heart, Lung, and Blood Institute. The grant will be used to further develop the proprietary technology for generating cell based therapies for the treatment of human disease.

TEQ Analytical Labs

Lab/Office: 175

Contact: JJ Slatkin

303-807-1868

jslatkin@teqanalyticallabs.com

http://www.teqanalyticallabs.com/

TEQ Analytical Laboratories is the premier state of the art cannabis testing laboratory in the State of Colorado. Located at Bioscience 1 on the Anschutz Medical Campus, TEQ occupies a brand new, custom built 5,200 square foot laboratory.

Touch of Life Technologies

Lab/Office: 350

Contact: Dr. Vic Spitzer

720-859-4140

vic.spitzer@toltech.net

The human body is complex and beautiful. Artists through the ages have studied the human body in detail and healers have dissected and catalogued it. In 1993 scientists at the University of Colorado created the Visible Human by milling away millimeter slices of a cadaver and photographing the remaining block, thereby digitizing the anatomy. In this way they took the fascination we have for our own anatomy and brought it into the information age. Touch of Life Technologies (ToLTech) is the sole licensee of these innovations and is creating products that will allow students, practitioners and the public in general to better see, feel, and understand the beauty and complexity of the human body.

UBPBio

Lab/Office: 222

Contact: Changwei Liu

720-273-5839

Changwei.liu@ubpbio.com

UBPBio manufactures and sells bioreagents related to the ubiquitin-proteasome pathway. The ubiquitinproteasome pathway is responsible for degradation of the majority of cellular proteins.

Verkko Biomedical LLC

Lab/Office: 100

Contact: Inga Tamayo
303-667-5842
inga@verkkobiomedical

Verkko Biomedical, LLC was formed on December 12, 2012 in the State of Colorado by Dr. Reed Ayers and Inga Tamayo. Reed Ayers is the inventor of the patented combustions synthesis technology for beta phase tricalcium phosphate manufacturing at Colorado School of Mines (CSM). Verkko Biomedical was formed to commercialize the combustion synthesis technology and manufacture medical grade customized alpha-, betaphase tricalcium phosphates (α-TCP, β-TCP) as precursor components for customers who operate in the biomedical/medical industry. Verkko will be operating in ceramic segment of the biomaterials market. This market is expected to reach $13.5 billion by 2015, growing at CAGR of 11% from 2008 to 2015. The US market is expected to account for nearly 42% of the total revenues.

VisuGen Global, LLC

Lab/Office: 216

Contact: John Gerdes
303-919-6018
visugen.jg@gmail.com

VisuGen Global will advance a new proprietary approach to concentrate and detect gene targets in a method that is simple to perform anywhere needed. The products will have high impact in that testing will be enabled in global regions and in on site locations where rapid results inform an actionable response. The technology is innovative and transformational and addresses unmet testing demands and broad based market opportunities.

Vitan-Biotech LLC

Lab/Office: 222

Contact: Xichun (Mark) Zhou
zhouxc@vitan-biotech.com
303 717-4518

Vitan-Biotech LLC is an innovative company focusing on the developing nanobiotechnology for use in scientific research tools, biosensors, biochips/microarrays, nanopore sequencing, disease diagnostics and nucleic acid delivery. The company is currently engaged in developing novel Raman biotag for ultrasensitive infectious disease biomarker detection, in Slide-Based ELISA, IFA/IHC Immunoassays for Quantitation of low abundance but high value cancer biomarkers in clinical specimen, as well as in developing operation-free diagnostic kit for Far-forward Fieldable Applications. Vitan-Biotech's nanobiotechnology will generate highly sensitive and economical assay platforms and diagnostic tools for clinical diagnosis and personalized care of the patient.

Western States Pathology

Lab/Office: 100M

Contact: Dr. Robert Greer
303-619-5229
robert.greer@ucdenver.edu

Western States Regional Oral & Maxillofacial Pathology Laboratory has been in continuous operation since 1978. It is the largest free-standing oral & maxillofacial pathology laboratory west of the Mississippi and has a regional referral base that includes ten states. The laboratory offers a large variety of pathology services including evaluation of tissue samples, consultative opinions, direct immunofluorescence and molecular pathology. The lab also offers advanced histochemical analysis of biopsy specimens and can provide in situ hybridization studies for clients as necessary. The medical director is a board certified oral & maxillofacial pathologist and the laboratory is licensed by CLIA (Clinical Laboratory Improvement Amendments).

---

yuScience, LLC

Lab/Office: 131
Contact: Xiaoli Yu
303-842-7276
Xiaoli@yuScience.com
yuScience is focusing on the development of early disease biomarkers in patients with multiple sclerosis (MS). They are investigating the immune-pathogenesis of MS, and identifying key players in disease progression.

Zalgen Labs, LLC

Lab/Office: 324
Contact: Matt Boisen
Mboisen24@gmail.com
303-775-7752
www.zalgenlabs.com
Zalgen Labs is a biotechnology company specializing in the design and production of superior biological molecules critical for the development and commercialization of reliable, rapid, and affordable diagnostic platforms, immunotherapeutics, and novel vaccines targeting neglected and underrepresented human infectious diseases. The company makes use of its proprietary expression platforms, including its patented mammalian cell-based biomanufacturing system, CHOLCelect, to deliver next generation biologicals to world health and biodefense settings.

Z Biotech, LLC

Lab/Office: 214
Contact: Jian Zhang
jzhang@zbiotech.com
970- 217-6414
Z Biotech, LLC is dedicated to the advance of life science research and product development through the development and commercialization of innovative microarray platforms and carbohydrate standards. The goal of Z Biotech is to establish advanced carbohydrate libraries and to take these new products to multiplex microarray assays and eventually development of clinical diagnostics.

Zenith BioPharma, LLC

Lab/Office: 214
Contact: Jian Zhang
jzhang@zbiotech.com
970- 217-6414
Zenith BioPharma, LLC is a cancer therapeutics research and development company. Current status of Zenith is to complete proof-of-concept in about one year. Our unique focus is cancer therapeutics targeting cancer stem cells, cancer metastasis and recurrence. The company was founded by Drs. Jian Zhang, Yan Qi and Shilong Lu. Zenith is currently self-funded ($15,000).